Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Crowdfunding Helps Solve Rare Disease Mystery

February 12, 2015 2:40 pm | by Tel Aviv University | News | Comments

Rare diseases — those that affect fewer than one in 200,000 people — are often identified early in life. Some 30 percent of children afflicted by these "orphan diseases" do not live to see their fifth birthday. Read more...


Science is Afire With Plans to Help Smokers Quit

February 12, 2015 12:25 pm | by Cynthia Fox, Science Editor | Articles | Comments

All types of scientists are at work, on all kinds of quit-smoking aids, from an anti-smoking vaccine to a biomarker test. Read more...                                         


Commuter with Measles Prompts California Transit Warning

February 12, 2015 11:48 am | by Paul Elias, Associated Press | News | Comments

​Officials in Northern California on Wednesday warned Bay Area Rapid Transit commuters that they may have been exposed to measles after an infected LinkedIn employee used the trains. Read more...                 


Eisai's Thyroid Cancer Drug: Phase 3 Trial

February 12, 2015 11:38 am | News | Comments

Results from the pivotal Phase 3 SELECT (Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) were published online in the New England Journal of Medicine (NEJM). Read more..


Cumberland Pharmaceuticals: Pipeline Expansion with AERD Drug

February 12, 2015 11:10 am | News | Comments

Cumberland Pharmaceuticals Inc. announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin exacerbated respiratory disease (AERD). Read more..


J&J Projects Aim to Spot Who'll Get a Disease

February 12, 2015 10:59 am | by Associated Press | News | Comments

Imagine being able to identify people likely to develop a particular disease - and then stop it before it starts. This isn't a science fiction tale. It's the ambitious goal of three research projects just launched by Johnson & Johnson's pharmaceutical research arm, Janssen Research & Development, that the company says are aimed at redefining health care. Read more...


Scientists Overturn Dogma on Bubonic Plague

February 12, 2015 9:13 am | by University of North Carolina at Chapel Hill | News | Comments

For decades, scientists have thought the bacteria that cause the bubonic plague hijack host cells at the site of a fleabite and are then taken to the lymph nodes. Read more...              


Research Finds Increase in Newborn Opioid Withdrawal in Ontario

February 12, 2015 9:06 am | by Leslie Sheperd, St. Michaels Hospital | News | Comments

Scientists found that this withdrawal increased 15-fold over 20 years. Read more...                             


Sequence of Genetic Mutations Determine How Cancer Behaves

February 12, 2015 9:01 am | by University of Cambridge | News | Comments

Researchers show for the first time that the order in which such mutations occur can have an impact on disease severity and response to therapy. Read more...                 


Liberia President Calls for Zero Ebola Cases, Vigilance

February 12, 2015 8:51 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Liberia's president vowed Wednesday that the country would get to zero Ebola cases soon as the U.S. military announced it will be withdrawing most of its troops. Read more...              


AbbVie Submits NDA in Japan for Hepatitis C Treatment

February 12, 2015 8:46 am | News | Comments

The NDA is supported by positive results from a Phase 3 study. Read more...                               


Qiagen's Tuberculosis Treatment Preferred in Large Study

February 11, 2015 4:49 pm | News | Comments

Groundbreaking clinical data published in the The Lancet medical journal showed that reliance on the 100-year-old tuberculin skin test has significantly overestimated latent tuberculosis infections in China, while results in the same patients using the QuantiFERON-TB Gold (QFT) from QIAGEN N.V. provided a far better understanding of disease burden. Read more...


Unwanted Impact of Antibiotics Broader, More Complex

February 11, 2015 11:15 am | News | Comments

​Researchers at Oregon State University have discovered that antibiotics have an impact on the microorganisms that live in an animal's gut that's more broad and complex than previously known. The findings help to better explain some of the damage these medications can do, and set the stage for new ways to study and offset those impacts. Read more...


Rite Aid Spends $2B on Push Into Pharmacy Benefit Management

February 11, 2015 10:45 am | News | Comments

Drugstore chain Rite Aid will use a $2 billion purchase of EnvisionRx to stretch its reach into managing pharmacy benefits in a deal that also builds its stake in two hot growth areas, specialty pharmaceuticals and Medicare prescription drug coverage. Read more...


Screening Tool Could Speed Ovarian Cancer Drug Development

February 11, 2015 10:38 am | News | Comments

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.